STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

NASDAQ:STOK • US86150R1077

31.45 USD
+0.36 (+1.16%)
Last: Feb 18, 2026, 11:40 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to STOK. STOK was compared to 521 industry peers in the Biotechnology industry. STOK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. STOK has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year STOK was profitable.
  • In the past year STOK had a positive cash flow from operations.
  • STOK had negative earnings in each of the past 5 years.
  • STOK had a negative operating cash flow in each of the past 5 years.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • STOK's Return On Assets of 11.39% is amongst the best of the industry. STOK outperforms 94.05% of its industry peers.
  • STOK's Return On Equity of 13.32% is amongst the best of the industry. STOK outperforms 93.86% of its industry peers.
  • STOK has a better Return On Invested Capital (6.66%) than 92.90% of its industry peers.
Industry RankSector Rank
ROA 11.39%
ROE 13.32%
ROIC 6.66%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • STOK's Profit Margin of 19.96% is amongst the best of the industry. STOK outperforms 93.28% of its industry peers.
  • STOK has a Operating Margin of 13.06%. This is amongst the best in the industry. STOK outperforms 92.13% of its industry peers.
Industry RankSector Rank
OM 13.06%
PM (TTM) 19.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • STOK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for STOK has been increased compared to 1 year ago.
  • STOK has more shares outstanding than it did 5 years ago.
  • STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 20.30 indicates that STOK is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 20.30, STOK belongs to the best of the industry, outperforming 89.83% of the companies in the same industry.
  • STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 20.3
ROIC/WACC0.77
WACC8.68%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 6.53 indicates that STOK has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.53, STOK is in the better half of the industry, outperforming 66.60% of the companies in the same industry.
  • STOK has a Quick Ratio of 6.53. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
  • STOK's Quick ratio of 6.53 is fine compared to the rest of the industry. STOK outperforms 67.37% of its industry peers.
Industry RankSector Rank
Current Ratio 6.53
Quick Ratio 6.53
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 135.71% over the past year.
  • Looking at the last year, STOK shows a very strong growth in Revenue. The Revenue has grown by 1128.17%.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.3%
Revenue 1Y (TTM)1128.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%117.25%

3.2 Future

  • Based on estimates for the next years, STOK will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.55% on average per year.
  • The Revenue is expected to grow by 84.05% on average over the next years. This is a very strong growth
EPS Next Y111.66%
EPS Next 2Y-36.2%
EPS Next 3Y-14.81%
EPS Next 5Y18.55%
Revenue Next Year939.02%
Revenue Next 2Y37.54%
Revenue Next 3Y52.87%
Revenue Next 5Y84.05%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • STOK is valuated quite expensively with a Price/Earnings ratio of 41.93.
  • 91.75% of the companies in the same industry are more expensive than STOK, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.16. STOK is valued rather expensively when compared to this.
  • The Forward Price/Earnings Ratio is negative for STOK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 41.93
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of STOK indicates a rather cheap valuation: STOK is cheaper than 90.98% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, STOK is valued cheaply inside the industry as 93.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 34.18
EV/EBITDA 47.41
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • STOK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • STOK's earnings are expected to decrease with -14.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y-36.2%
EPS Next 3Y-14.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • STOK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

STOKE THERAPEUTICS INC

NASDAQ:STOK (2/18/2026, 11:40:45 AM)

31.45

+0.36 (+1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-11
Inst Owners119.96%
Inst Owner Change3.86%
Ins Owners3.99%
Ins Owner Change-45.38%
Market Cap1.80B
Revenue(TTM)205.63M
Net Income(TTM)41.05M
Analysts86.25
Price Target36.47 (15.96%)
Short Float %20.41%
Short Ratio14.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.64%
Min EPS beat(2)-12.12%
Max EPS beat(2)23.41%
EPS beat(4)3
Avg EPS beat(4)159.13%
Min EPS beat(4)-12.12%
Max EPS beat(4)558.67%
EPS beat(8)7
Avg EPS beat(8)85.57%
EPS beat(12)10
Avg EPS beat(12)60.58%
EPS beat(16)12
Avg EPS beat(16)28.75%
Revenue beat(2)2
Avg Revenue beat(2)60.62%
Min Revenue beat(2)52.02%
Max Revenue beat(2)69.22%
Revenue beat(4)4
Avg Revenue beat(4)553.32%
Min Revenue beat(4)52.02%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)289.38%
Revenue beat(12)10
Avg Revenue beat(12)187.93%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.42%
PT rev (3m)26.67%
EPS NQ rev (1m)2.68%
EPS NQ rev (3m)-4.53%
EPS NY rev (1m)13.68%
EPS NY rev (3m)-33.91%
Revenue NQ rev (1m)10.66%
Revenue NQ rev (3m)9.77%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)2.39%
Valuation
Industry RankSector Rank
PE 41.93
Fwd PE N/A
P/S 8.74
P/FCF 34.18
P/OCF 33.87
P/B 5.83
P/tB 5.83
EV/EBITDA 47.41
EPS(TTM)0.75
EY2.38%
EPS(NY)-3.12
Fwd EYN/A
FCF(TTM)0.92
FCFY2.93%
OCF(TTM)0.93
OCFY2.95%
SpS3.6
BVpS5.39
TBVpS5.39
PEG (NY)0.38
PEG (5Y)N/A
Graham Number9.54
Profitability
Industry RankSector Rank
ROA 11.39%
ROE 13.32%
ROCE 8.43%
ROIC 6.66%
ROICexc 30.2%
ROICexgc 30.2%
OM 13.06%
PM (TTM) 19.96%
GM N/A
FCFM 25.56%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 25.22%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 184.52%
Profit Quality 128.04%
Current Ratio 6.53
Quick Ratio 6.53
Altman-Z 20.3
F-Score8
WACC8.68%
ROIC/WACC0.77
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.3%
EPS Next Y111.66%
EPS Next 2Y-36.2%
EPS Next 3Y-14.81%
EPS Next 5Y18.55%
Revenue 1Y (TTM)1128.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%117.25%
Revenue Next Year939.02%
Revenue Next 2Y37.54%
Revenue Next 3Y52.87%
Revenue Next 5Y84.05%
EBIT growth 1Y122.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.24%
EBIT Next 3Y-15.58%
EBIT Next 5Y31.31%
FCF growth 1Y162.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y164.06%
OCF growth 3YN/A
OCF growth 5YN/A

STOKE THERAPEUTICS INC / STOK FAQ

What is the fundamental rating for STOK stock?

ChartMill assigns a fundamental rating of 5 / 10 to STOK.


Can you provide the valuation status for STOKE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to STOKE THERAPEUTICS INC (STOK). This can be considered as Fairly Valued.


Can you provide the profitability details for STOKE THERAPEUTICS INC?

STOKE THERAPEUTICS INC (STOK) has a profitability rating of 4 / 10.


What is the expected EPS growth for STOKE THERAPEUTICS INC (STOK) stock?

The Earnings per Share (EPS) of STOKE THERAPEUTICS INC (STOK) is expected to grow by 111.66% in the next year.